Anixa Biosciences is trading at $3.60 (+5.88%) in pre-market following a modest late-week rebound despite a lack of fresh company-specific news.
- The upward movement occurs amid firmer broader risk sentiment, providing a lift to the biotech sector which has seen significant volatility recently.
- While investor attention has recently centered on the company's clinical progress and patent protections, no new catalysts were reported for the July 20 session.